Antimicrobial salt solutions for food safety applications

Information

  • Patent Grant
  • 8486472
  • Patent Number
    8,486,472
  • Date Filed
    Thursday, January 18, 2007
    17 years ago
  • Date Issued
    Tuesday, July 16, 2013
    11 years ago
Abstract
Antimicrobial formulations and solutions for food safety and quality applications are disclosed. Because some of these formulations and solutions contain a substantial concentration of salt, they are adaptable to a variety of food-processing applications, such as for chilling brine applications, disinfecting meat baths/rinses, beef injection brines, poultry chill tanks, brines used in cheese manufacture, as a wash to kill salmonella and other bacteria on hard-boiled eggs or egg shells, and as a wash to disinfect produce, which can become contaminated with salmonella and other pathogenic bacteria in the field. These uses of concentrated salt solutions that depress the freezing point of the solution provide a low temperature bath or shower in which food products can be cooled. One embodiment comprises between 25 ppm and 100,000 ppm surfactant and between 72% and 99.99% salt. This blend can then be dissolved in water to make a solution of between about 1% total solids by weight up to the saturation point, which can be used as an antimicrobial solution for food safety applications.
Description
FIELD OF THE INVENTION

This invention relates to antimicrobial solutions for food safety and quality applications.


BACKGROUND OF THE INVENTION

The prevention of contamination of food product by pathogenic microorganisms is important to protect public health. The reduction of spoilage microorganisms in food manufacturing facilities can extend product shelf lives and reduce the amount of food that is discarded as waste. There is a need for improved methods of controlling microorganisms in food production plants. Microorganisms can accumulate at a variety of different points in a food manufacturing operation; the more points at which viable microorganisms can be controlled, the lower the chances of food contamination and the safer the manufacturing process.


The use of acid-anionic surfactants as antibacterial agents is known. These agents have limited utility in environments where operation at low temperature is required, as their effectiveness drops off significantly at lower temperature and, of course, operation below 0° C. is typically prevented by freezing. Their activity is also directly dependent on maintaining a relatively low pH, with activities dropping rapidly above pH 3.


Other antibacterial agents have been identified, but their use is problematic due to their non-food quality status. For example, a wide variety of chemical disinfecting agents are in use in food plants. However, there are often disadvantages to these chemicals. In some instances they are too toxic to come into direct contact with the food itself, and may present worker safety or environmental waste disposal issues. In other instances they are insufficiently effective to provide adequate kill of microorganisms, especially at low temperatures. Additionally, the relatively high cost of these chemicals adds to the cost of food production and, consequently, increases the cost of the end product itself.


Salt has been used for thousands of years as a food preservative. Often, however, salt solutions alone are not sufficiently effective as antibacterial agents, as they do not provide a speedy mechanism for killing unwanted bacteria that permits their exclusive use in food processing environments. Also there are certain pathogenic microorganisms that survive very well in salt brines even at cold temperatures, such as Listeria monocytogenes.


Thus, a problem associated with the antimicrobial solutions for food safety applications that precede the present invention is that they do not provide an improved antimicrobial solution for food safety applications having operating parameters adaptable to a multiplicity of applications in the food processing industry.


Another problem associated with the antimicrobial solutions for food safety applications that precede the present invention is that they do not provide an antimicrobial solution for food safety applications having safe, acceptable ingredients for use in food processing to prevent bacteria from accumulating in food processing operations.


Yet another problem associated with the antimicrobial solutions for food safety applications that precede the present invention is that they do not provide an antimicrobial solution for food safety applications that can be used at temperatures below room temperature, and preferably below the normal freezing point of water (0° C.).


Still a further problem associated with the antimicrobial solutions for food safety applications that precede the present invention is that they may contain or lead to toxic and/or environmentally undesirable additives. For example, they may contain quaternary ammonium chloride as the anti-bacterial ingredient, or they may form chlorinated or brominated byproducts, or they may contain phosphates.


Yet another problem associated with the antimicrobial solutions for food safety applications that precede the present invention is that they do not provide an antimicrobial solution for food safety applications that is relatively inexpensive to purchase, use and maintain.


Yet another problem associated with some of the antimicrobial solutions for food safety applications that precede this invention is that they require low pH for effectiveness, and low pH solutions have detrimental effects on concrete floors and can contribute to corrosion of equipment. There is a need for antimicrobial solutions which are highly effective at neutral or near neutral pH.


For the foregoing reasons, there has been defined a long felt and unsolved need for an improved antimicrobial solution for food safety applications.


SUMMARY OF THE INVENTION

An embodiment of the invention described herein is a food-safe solution or composition for use in solution that may be used in a variety of applications to control microorganisms in food plant operations, including the disinfection of food processing brines. The solution or composition of said embodiment may comprise surfactant and salt. The salt can be selected from inorganic salts such as the sodium, potassium, magnesium, calcium, iron, and ammonium salts of chloride, sulfate, nitrate, phosphate, carbonate and hydroxide or organic salts such as the sodium, potassium, magnesium, calcium and ammonium salts of formate, acetate, gluconate, propionate, and hydroxypropionate. Suitable surfactants may include sodium lauryl sulfate, linear alkylbenzene sulfonates, alcohol sulfates, alkyl sulfates, alkyl sulfonates, sodium alkyl methyltaurines, alpha-olefin sulfonates, alcohol ethoxylates, nonylphenyl ethoxylates, alkylpolyglucosides, fatty alcohols, fatty acids and fatty acid salts, lignosulfonates and lignin derivatives, hydroxypoly(oxyethylene) derivatives, fatty alkanolamides, fatty amine oxides, sodium dioctylsulfosuccinate, dodecylbenzene sulfonic acid and salts thereof, the sodium salt of sulfonated oleic acid, sodium dodecylbenzene sulfonate, lauramine oxide, dodecyldiphenyloxide-disulfonic acid and salts thereof.


These and other aspects of the present invention are elucidated further in the detailed description.







DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The following description of the invention is intended to illustrate various embodiments of the invention. As such, the specific modifications discussed are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of the invention, and it is understood that such equivalent embodiments are to be included herein.


It has been discovered that salts act synergistically with surfactant ingredients to provide a significant and unexpected increase in antibacterial effectiveness in solution.


In one embodiment of the present invention, a formulation for food safety applications is provided comprising surfactant and salt, and solutions comprising said formulation. In another embodiment of the present invention, a formulation for food safety applications is provided comprising acid, surfactant and salt, and solutions comprising said formulation.


Many applications for these and other embodiments according to the present invention are envisioned. One application is for disinfecting a food processing bath or rinse. For example, a solution of an antimicrobial composition according to the present invention could be used in or as a chill brine to minimize the bacterial contamination of the chill brine.


Further, bacterial contamination during slaughter is typically highest at the surface of the meat, and these solutions may be used as a method to kill bacteria directly on the meat surface in a manner that is food safe and will impart no toxic chemicals to the meat. A solution of the antimicrobial composition could be sprayed or showered on to animal carcasses or the carcasses could be directly immersed in a bath of the solution. The brine could be pre-chilled to provide a simultaneous cooling and disinfection. The antimicrobial brine can also be used to wash animals prior to slaughter, to minimize contamination from the animals' hides, skins or feathers. It can also be used as a disinfection wash/chill step for beef trim and other further processed meat and poultry parts.


Another application for some embodiments of the present invention is for beef injection brines. Brines are injected into enhanced beef products, and there is concern that the brine may drive bacteria, such as E. coli O157:H7, from the surface into internal areas of the meat. Cooking intact cuts of beef to rare or medium rare doneness could then lead to food-borne illness. Another concern is that the brine, which is recycled in the process, will become contaminated. Under the current regulatory environment, it is crucial that beef processors are able to prove lot-to-lot separation. Use of a validated antimicrobial in the injected brine solution could prevent the brine injection system from tying together multiple production lots. Other potential uses in the meat industry include hide curing, offal chilling and natural casing preservation.


In the poultry industry, contamination of the carcasses by Salmonella spp. and Campylobacter spp. is a major public health concern. Some embodiments according to the present invention could be used in poultry chill tanks to reduce this contamination and provide an energy-efficient cooling step, thus improving product shelf life and quality.


Brines used in cheese manufacture present another application for embodiments of the present invention. Cheese manufacture often involves a prolonged soak in concentrated brine. This step can introduce a significant risk for L. monocytogenes contamination. This risk could be minimized through the use of an antimicrobial salt solution in the brine.


Yet another application is as a wash to kill salmonella on eggs. Also, hard-boiled eggs are often pre-disinfected and shipped in brine. Use of some embodiments of the present invention would permit the disinfection step to be carried out in the storage brine itself. Yet another application is a wash to disinfect produce, which can become contaminated with salmonella and other pathogenic bacteria in the field.


Further it has been found that the salt/surfactant combination maintains antilisterial activity even in the presence of organic material. As the brine is recirculated in the meat processing facility, organic material (meat juice from leaking packages, meat from broken packages, debris rinsed from the outside of packages, etc.) can inhibit other antimicrobials such as chlorine. The salt/surfactant system maintained good activity despite the presence of this organic material.


The following examples further illustrate the synergistic and unexpected results from combining surfactant with salt.


Tests have identified a variety of surfactants which are extremely effective at killing L. monocytogenes in salt brines at neutral or near-neutral pH. These surfactants showed an unexpected and dramatic synergistic effect when used in combination with a salt. Tests were generally run according to the following procedure:

  • 1. Inoculate a separate tube containing approximately 10 ml of Brain Heart Infusion (BHI) broth with the following L. monocytogenes strains: H2446 (CDC Global Standard), Scott A (serotype 4b), 12243 (serotype 1/2a), and two strains isolated from the environment of a cooked meat and poultry facility, designated WP1, and WP4. Incubate the tubes at least 5 days at 7-10° C.+/−20° C.
  • 2. Assume the growth to be 109 cfu/ml. Serially dilute each culture in cold (˜7° C.). Butterfield's Phosphate Buffered Water (PBW) to 108 cfu/ml (1:10). Since five cultures of L. monocytogenes are being used as a cocktail, begin the dilution series using 2.20 ml of each culture added to 99 ml of PBW.
  • 3. Plate (-6, -7, -8) the diluted culture to get the starting count of the inoculum on Modified Oxford medium (MOX) using a thin agar overlay (TAL) technique (overlay with Trypticase Soy Agar [TSA]) to revive injured cells.
  • 4. Add 1 ml of the diluted cocktail to 100 ml of cold test solution.
  • 5. Mix the solutions well.
  • 6. Determine the L. monocytogenes population at time 0 and 4 hours. Plate-1 (0.1 ml on 1 plate), -2, -3, and 4 dilutions using spread plates on MOX TAL with TSA.
  • 7. Incubate the test solutions at test temperature for the duration of the experiment.
  • 8. Incubate the MOX TAL with TSA plates at 20° C.+/−2° C. for 72+/−3 hours. Count representative colonies, which are black, and multiply by the dilution factor.


Table 1 provides a summary of results of these tests on several different surfactants in solution either alone or in combination with 20% sodium chloride, wherein the solutions were incubated at 2° C. (+/−1° C.):









TABLE 1








L. monocytogenes (cfu/mL) after 4 Hours in Solutions at 2° C.









Solution Composition

L. mono count (cfu/mL)






Water (control)
7.1 × 104


20% NaCl (control)
1.0 × 105


50 ppm sulfonated oleic acid, Na salt
1.3 × 105


50 ppm sulfonated oleic acid, Na salt +
7.7 × 103


20% NaCl



50 ppm lauramine oxide
3.6 × 103


50 ppm lauramine oxide +
<10


20% NaCl



50 ppm fatty alkanolamide
1.1 × 104


50 ppm fatty akanolamide +
<10


20% NaCl



50 ppm nonylphenol ethoxylate
1.3 × 105


50 ppm nonylphenol ethoxylate +
 40


20% NaCl



50 ppm sodium linear alkylbenzene
5.9 × 103


sulfonate



50 ppm sodium linear alkylbenzene
<10


sulfonate + 20% NaCl



50 ppm alkyl polyglucoside
9.6 × 104


50 ppm alkyl polyglucoside +
 10


20% NaCl









As shown in Table 1, there is an unexpected and dramatic synergistic effect between sodium chloride and the surfactants in killing L. monocytogenes. It can be seen that L. monocytogenes survived in very high concentration in 20.0% NaCl. A solution comprising 50 ppm surfactant alone resulted in only a 0 to 1.3 log reduction in L. monocytogenes compared to plain water. However, when the surfactants were combined with 20.0% NaCl brine, the kill of L. monocytogenes rose to a >4 log reduction compared to the solution with only 20.0% NaCl and no surfactant.


Table 2 shows data from another experiment which was carried out to determine the effect of different salts and different salt concentrations in combination with surfactants on. L. monocytogenes survival in brines.









TABLE 2








L. monocytogenes (cfu/mL) after 4 Hours in Solutions at 2° C.









Solution Composition

L. mono count (cfu/mL)






Water (control)
5.45 × 105


20% NaCl (control)
4.0 × 105


20% Potassium Acetate
4.2 × 105


20% Sodium Acetate
3.0 × 104


20% Sodium Formate
3.6 × 105


50 ppm lauramine oxide
5.8 × 104


50 ppm lauramine oxide + 20% NaCl
<10


50 ppm lauramine oxide + 10% NaCl
<10


50 ppm lauramine oxide + 5% NaCl
<10


50 ppm lauramine oxide + 1% NaCl
2.1 × 104


50 ppm lauramine oxide + 20%
<10


Potassium Acetate



50 ppm lauramine oxide + 20% Sodium
<10


Acetate



50 ppm lauramine oxide + 20% Sodium
<10


Formate



50 ppm lauramine oxide + 20% MgSO4
<10


50 ppm lauramine oxide + 10% MgSO4
<10


50 ppm lauramine oxide + 5% MgSO4
<10


50 ppm lauramine oxide + 1% MgSO4
1.5 × 104


50 ppm C12(branched) sodium diphenyl
3.1 × 104


oxide disulfonate



50 ppm C12(branched) sodium diphenyl
<10


oxide disulfonate + 20% NaCl



50 ppm alcohol ethoxylate
1.9 × 105


50 ppm alcohol ethoxylate +
<10


20% NaCl



50 ppm sodium olefin sulfonate
1.8 × 105


50 ppm sodium olefin sulfonate +
<10


20% NaCl









Data in Table 2 again shows that while the surfactant alone or sodium chloride alone has little effect on the survival of L. monocytogenes in solution, the combination of even low concentrations of surfactant with sodium chloride in solution has a powerful cidal effect on L. mono, giving over 4 log kill or higher. The data run on a particular surfactant, in this case a lauramine oxide, shows that it can be “activated” to be highly cidal towards L. monocytogenes over a broad range of sodium chloride concentrations. In solutions containing 5% and 20% NaCl, 50 ppm of the surfactant was highly cidal towards L. monocytogenes. The data in Table 2 also shows that salts other than sodium chloride are effective. A variety of organic salts, including formates and acetates, as well as magnesium sulfate all showed the same ability to “activate” low concentrations of surfactant to kill L. monocytogenes in solution, even though the salts by themselves had little effect on the organisms.


Because some embodiments of the present invention contain a substantial concentration of salt, these embodiments are ideal for a variety of applications. For instance, they are ideal for chilling brine applications. Chilling brines make use of concentrated salt solutions that depress the freezing point of the solution to provide a low temperature bath or shower in which food products can be efficiently cooled. Bacterial contamination of the chill brine is a food safety hazard, requiring that the brine be frequently disposed and often requiring rigorous cleaning of the equipment to remove bacterial biofilms. Contamination by L. monocytogenes is of particular concern in many ready-to-eat meat, poultry, seafood and dairy processing chill brine applications because it is known to survive in high salt concentrations and because many of the currently available disinfectant chemicals are either not suitable for direct food contact or become ineffective at the cold temperatures of the chill bath. Brine chillers are used extensively to cool frankfurters and other sausage products in continuous-cook operations. Dozens of nationwide recalls and at least one large food-borne outbreak have been caused by L. monocytogenes contamination of these types of products.


One useful application for these formulas is in chill brines used in the manufacture of cooked sandwich meats, sausages, and links. U.S. patent application Ser. No. 10/460,769, filed Jun. 12, 2003, describes embodiments consisting of a surfactant and an acid together which worked synergistically with the salt in food production chill brines to kill L. monocytogenes. One drawback of these embodiments was their acidity, which could have detrimental effects on concrete floors and steel equipment. The present embodiment provides certain types of surfactants which are very effective when combined with either inorganic or organic salts in solution at killing L. monocytogenes even in the absence of an acidifying agent.


Several tests were carried out to determine the effectiveness of embodiments according to the invention in meat processing chill brines. In one experiment, brine was taken at the end of a production week from a brine chiller used in a ready to eat, cooked beef production line. The sodium chloride concentration in this brine was approximately 17%. Samples of the brine with and without added surfactant were inoculated with a cocktail of L. monocytogenes as per the procedure described above, incubated at 4° C. for four hours, and then plated to determine L. monocytogenes survival. Results are summarized in Table 3.









TABLE 3








L. monocytogenes (cfu/mL) after 4 Hours in Beef Plant Brine at 4° C.













L. mono count




Brine Composition
(cfu/mL)














Brine Control (no additive)
1.4 × 106



  50 ppm lauramine oxide
<10



  25 ppm lauramine oxide
<10



12.5 ppm lauramine oxide
<10



  50 ppm sodium linear alkylbenzene
<10



  25 ppm sodium linear alkylbenzene
<10



12.5 ppm sodium linear alkylbenzene sulfonate
<10



  50 ppm nonylphenol ethoxylate
<10



  25 ppm nonylphenol ethoxylate
<10



12.5 ppm nonylphenol ethoxylate
20



  50 ppm fatty alkanolaminde
<10



  25 ppm fatty alkanolaminde
<10



12.5 ppm fatty alkanolaminde
40



  50 ppm sodium olefin sulfonate
10



  25 ppm sodium olefin sulfonate
60



12.5 ppm sodium olefin sulfonate
110










The data in Table 3 indicate that the brine taken from the meat processing plant very easily supported the survival of L. monocytogenes, raising the possibility of a food safety hazard should contamination of the brine ever occur. However, addition of even small concentrations of a single surfactant provided >5 log kill of L. monocytogenes in the brine. The surfactants are effective at remarkably low concentration when in combination with salt in solution. As little as 12.5 ppm of several of the surfactants in Table 3 killed essentially all of the inoculum. This experiment was also significant because it indicates that the salt/surfactant combination maintains antilisterial activity even in the presence of organic material. As the brine is recirculated in the meat processing facility, organic material (meat juice from leaking packages, meat from broken packages, debris rinsed from the outside of packages, etc.) can inhibit other antimicrobials such as chlorine. The salt/surfactant system maintained good activity despite the presence of this organic material.


Often the effectiveness of antimicrobial additives decreases at lower temperatures. Another test was run to determine the effectiveness of these formulas in an even colder meat processing brine. Five samples of spent chill brine were obtained at different times from a hot dog manufacturing plant, which uses a nearly saturated sodium chloride brine at a temperature of approximately −20° C. The brine samples were tested with and without addition of 50 ppm of an alcohol ethoxylate surfactant in the same manner as described above, except they were incubated for 4 hours at −20° C. before plating. Results are shown in Table 4.









TABLE 4








L. monocytogenes (cfu/mL) after 4 Hours in Hot Dog



Plant Chill Brine at −20° C.













Brine
Brine
Brine + 50 ppm Alcohol




Sampling Date
Control
Ethoxylate








Jul. 7, 2005
1.5 × 105
<10




Jul. 14, 2005A
5.3 × 105
<10




Jul. 14, 2005B
2.8 × 105
<10




Mar. 18, 2005
5.7 × 105
<10




Jun. 10, 2005
4.9 × 105
<10




Apr. 19, 2005
6.5 × 105
<10










The data in Table 4 indicate that the process brines supported the survival of L. monocytogenes very well even at −20° C. However, addition of 50 ppm of alcohol ethoxylate resulted in kill of essentially the entire ˜5 log inoculum within 4 hours. Tests were subsequently run on even lower concentrations of the alcohol ethoxylate surfactant in the brine. Concentrations of 12.5 ppm were as effective as 50 ppm.


In addition to being effective against organisms in an aqueous solution, tests indicated that some embodiments of the invention were also effective against organisms in a biofilm. Biofilms can provide a haven for pathogens, increasing their resistance to antimicrobial treatments, and thereby providing another possible source of food contamination. Tests were run to see if some embodiments were effective against a L. monocytogenes biofilm. Challenge tests were run according to the procedure below. Test solutions were prepared from a sample of hot dog plant chill brine which was treated with various levels of the alcohol ethoxylate surfactant. Cooked turkey was added to the test solution before inoculation to simulate a worst case “dirty” brine with a high degree of organic load.

  • 1. Inoculate five cultures, L. monocytogenes H2446 (CDC Global Standard), Scott A-serotype 4b, 12243-serotype 1/2a, WP1 and WP4 in 10 ml Brain Heart Infusion broth (BHI). Incubate the tubes for 7 days at 10° C.+/−2° C.
  • 2. Aseptically dispense 50 ml of sterile Tryptic Soy Broth (TSB)+0.6% Yeast Extract (YE) into sterile disposable 50 ml conical shaped plastic tubes. Make enough tubes for each time point.
  • 3. Aseptically drop one coupon into the broth in each tube.
  • 4. Make a cocktail of the five cultures and add 0.1 ml into each tube. Incubate the tubes for 7 days at 7° C.+/−2° C.
  • 5. Dispense 40 ml of antimicrobial salt solutions containing sterile phosphate buffer into 50 ml plastic tubes.
  • 6. After biofilm has grown, aseptically remove coupon and rinse each side for 5 seconds with sterile distilled water to remove unattached cells.
  • 7. Aseptically drop each rinsed coupon into the antimicrobial salt solution tube and incubate for appropriate time (1 hour and 24 hour) at −20° C.+/−2° C.
  • 8. Aseptically add 45 ml of sterile phosphate buffer (PBW) to 50 ml conical shaped plastic tubes along with 10 sterile glass beads.
  • 9. After incubate time is complete, aseptically move the coupon from the antimicrobial salt solution to the sterile (PBW) solution containing beads.
  • 10. Shake the tube with glass beads for about 2 minutes to remove attached cells.
  • 11. Plate the cells in the PBW solution on TSA+0.6% YE using appropriate dilutions and incubate at 20° C. for 72+/−2 hours.
  • 12. Plate the antimicrobial salt solution on TSA+0.6% YE using appropriate *dilutions and incubate 20° C. for 72+/−2 hours. *Please make note: The first dilution should take place in 9 ml DE Neutralizing Buffer. After incubation, count typical colonies and record results to cfu/g.


Results of this challenge study are given in Table 5.









TABLE 5








L. mono Biofilm Challenge in Hot Dog Plant Chill Brine at −20° C.










Surfactant




Concentration
1 hour (cfu/coupon)
24 hours (cfu/coupon)












Control (0 ppm)
44,000
9700


15 ppm alcohol ethoxylate
5,000
5600


25 ppm alcohol ethoxylate
3500
250


50 ppm alcohol ethoxylate
10-100
<10









As shown in Table 5, it appears that even at the near neutral pH of the plant chill brine, low concentrations of surfactant are effective at killing L. monocytogenes in a biofilm. In this experiment, higher concentrations of surfactant were required to achieve 4 log kill than was seen in the solution challenge studies. This may be due to the greater resistance of the biofilm, but it also may be due to the brine being made very “dirty” with high organic loading in this experiment. Even with very “dirty” brine, 50 ppm alcohol ethoxylate showed >2 log kill of the biofilm within 1 hour and showed >3 log kill after 24 hours.


Tests were run to determine the effectiveness of formulas against organisms other than L. monocytogenes. Uncharacterized microorganisms were cultured from a sample of raw ground beef and used to challenge 24% sodium chloride brines with and without different surfactants. The test solutions were inoculated with the ground beef organism culture and incubated for 4 hours at −5° C. before plating. Results are given in Table 6.









TABLE 6







Total Plate Count (cfu/mL) after 4 Hours in 24% NaCl Brine at −5° C.








Brine Composition
Total plate count (cfu/mL)





Brine Control (no additive)
6.3 × 105


800 ppm nonylphenolethoxylate
40


800 ppm sodium salt of sulfonated oleic
5.2 × 103


acid



800 ppm alcohol ethoxylate
<10


800 ppm Toximul 3479F
<10


800 ppm sodium linear alkylbenzene
<10


sulfonate



800 ppm C12(branched) sodium diphenyl
1.0 × 103


oxide disulfonate + 20% NaCl



800 ppm Toximul TA-5
20


800 ppm Toximul 8382
7.8 × 103


800 ppm decyl alcohol ethoxylate, POE-6
10


800 ppm Toximul 3409F
160


800 ppm Toximul 3455F
60









Data in Table 6 indicates that a number of surfactants in combination with brine are also effective in killing the total plate count organisms found in raw ground beef.


In another embodiment of the present invention, an unexpected synergistic effect has also been found between acid, sodium chloride and sodium lauryl sulfate (SLS) antibacterial additive. Replicate tests were run to determine if this effect was statistically significant. Ten percent by weight solutions were prepared of a formula of 0.6% citric or malic acid, 100 ppm SLS, and 99.4% sodium chloride. Solutions were also prepared containing an identical concentration of acid and SLS but no sodium chloride. A bacterial culture suspension (Escherichia coli ATCC 11229) that had been incubated for 24 hours in Brain Heart Infusion (BHI) broth and had an initial inoculum count of about 109 CFU/ml was serially diluted in cold Butterfield's Phosphate Buffered Water (BPBW) to 105 CFU/ml. A 1.0 ml aliquot of this suspension was added to 100 ml of test solution at room temperature and mixed well, providing an initial inoculum of 103 CFU/ml. After 30 minutes, the E. coli populations were enumerated by plating on tryptic soy agar (TSA), making serial dilutions as necessary in BPBW. Plates were incubated at 35° C.+/−2° C. for approximately 24 hours. Colonies were then counted and compared to the initial inoculum counts. Results of these tests run on 16 replicates of each test solution are given in Table 7.









TABLE 7







Effectiveness of Acid/SLS Solutions with and without Salt on E. coli









Average Concentration of E. Coli


Test Solution
(CFU/ml)











citric acid, SLS, with salt
540


citric acid, SLS, without salt
1054


malic acid, SLS, with salt
141


malic acid, SLS, without salt
2419









Referring to Table 7, it can be seen that for both the citric acid/SLS and malic acid/SLS additives, the number of bacteria remaining alive after 30 minutes is much lower when salt is present than when there is no salt present. Analysis of the data indicates that there is a statistically significant increase in kill in the presence of salt (p<0.05). In contrast, a 10% solution of pure sodium chloride does not provide any significant kill of the test microorganisms.


To study chilling brine application of the current embodiment, tests were run on 17% by weight solutions of formulas consisting of between 0.3% and 6.0% citric acid, between 50 and 500 ppm SLS, and between 94% and 99.7% sodium chloride. Test solutions were cooled to −7° C. and inoculated with several strains of L. monocytogenes. Within 4 hours most solutions showed a 3 log kill of microorganisms and within 24 hours nearly all solutions showed no measurable plate count of the inoculum. A brine solution made up of sodium chloride alone caused less than a 1 log reduction of the L. monocytogenes over a 24-hour period.


An experiment was run to determine if solutions containing sodium chloride, sodium lauryl sulfate, and various acids would kill L. monocytogenes at cold temperatures. The following test procedure was used: A bacterial culture suspension (L. monocytogenes H2446 [CDC Global Standard]; Scott A-serotype 4b; 12243-serotype 1/2a; and a recent cooked meat and poultry facility isolate, WP4) that had been incubated for at least 5 days in BHI broth and had an initial inoculum count of about 109 CFU/ml was serially diluted in cold BPBW to 105 CFU/ml. A 1.0 ml aliquot of this suspension was added to 100 ml of cold (−7° C.+2° C.) test solution and mixed well, providing an initial inoculum of 103 CFU/ml. The test solutions were incubated at −7° C.+/−2° C. for the duration of the experiment. At intervals of 0, 4, and 24 hours the L. monocytogenes populations in the test solutions were determined on Modified Oxford agar (MOX). MOX plates were incubated at 35° C.+/−2° C. for approximately 48 hours. Colonies were then counted and compared to the initial inoculum counts.


Results are given in Table 8. Each test solution was a 17% by weight solution of the listed formula prepared in soft water.









TABLE 8







Effect of Solutions of NaCl, SLS and various acids


on L. monocytogenes














4 hr
24 hr





Time 0
CFU/
CFU/

Water


Sample
CFU/ml
ml
ml
pH
Activity















100% NaCl
1550
1250
1170
7.88
0.88


2.0% Malic Acid 500 ppm SLS
0
0
0
1.21
ND


98.0% NaCl


Water Control
1270
400
0
9.34
 0.999


0.3% Malic Acid 100 ppm SLS,
480
5
0
4.1
ND


99.7% NaCl


0.5% Malic Acid, 100 ppm SLS,
176
0
0
3.31
ND


99.5% NaCl


0.7% Malic Acid, 100 ppm SLS,
117
0
0
2.99
0.88


99.3% NaCl


0.3% Citric Acid, 500 ppm SLS,
5
0
0
4.14
ND


99.7% NaCl


0.5% Citric Acid, 500 ppm SLS,
0
0
0
3.37
ND


99.5% NaCl


0.7% Citric Acid, 500 ppm SLS,
0
0
0
2.98
0.88


99.3% NaCl


0.3% Malic Acid, 500 ppm SLS,
11
0
0
4.15
ND


99.7% NaCl


0.5% Malic Acid, 500 ppm SLS,
3
0
0
3.39
ND


99.5% NaCl


0.7% Malic Acid, 500 ppm SLS,
0
0
0
3.06
 0.879


99.3% NaCl


1.0% Citric Acid, 500 ppm SLS,
0
0
0
2.69
ND


99.0% NaCl


1.0% Malic Acid, 500 ppm SLS,
0
0
0
2.81
ND


99.0% NaCl


2.0% Lactic Acid, 500 ppm
0
0
0
2.65
0.885


SLS, 98.0% NaCl


2.0% Phosphoric Acid (75%),
0
0
0
1.52
0.884


500 ppm SLS, 98.0% NaCl


1.0% Benzoic Acid, 500 ppm
0
0
0
3.93
0.879


SLS, NaCl


2.0% Citric Acid, 500 ppm SLS,
0
0
0
2.3
0.884


98.0% NaCl


2.0% Malic Acid, 500 ppm SLS,
0
0
0
2.46
0.882


98.0% NaCl









In another experiment, 17% by weight solutions of formulas containing various levels of sodium chloride, citric acid, and sodium lauryl sulfate were tested for effectiveness in killing L. monocytogenes at cold temperatures. The same test procedure was used as described above, except test solutions were plated on MOX with a Thin Agar Overlay of TSA (to aid in the recovery of injured cells). Results are given in Table 9. The data indicate that the relative amounts of acid and surfactant can be varied to suit different applications. A shown in table 9, in pH sensitive applications, the acid may be decreased without losing effectiveness. Similarly, in applications where a lower level of surfactant is desired, the performance can be maintained by raising the concentration of acid.









TABLE 9







Effect of Solutions of NaCl, SLS, and Citric Acid on



L. monocytogenes at −6.7° C.













Time 0
4 hr
24 hr



Sample
CFU/ml
CFU/ml
CFU/ml
pH














100% NaCl
~7000
~6250
2290
7.66


0.3% Citric Acid, 50 ppm SLS,
~4940
163
0
4.19


99.7% NaCl






0.3% Citric Acid, 100 ppm SLS,
2230
97
0
4.27


99.7% NaCl






0.3% Citric Acid, 150 ppm SLS,
3080
105
0
4.3


99.7% NaCl






0.3% Citric Acid, 200 ppm SLS,
1970
42
0
4.28


99.7% NaCl






0.3% Citric Acid, 300 ppm SLS,
1490
20
0
4.3


99.7% NaCl






0.3% Citric Acid, 400 ppm SLS,
221
1
0
4.29


99.7% NaCl






0.3% Citric Acid, 500 ppm SLS,
99
0
0
4.32


99.7% NaCl






0.5% Citric Acid, 50 ppm SLS,
3360
0
0
3.54


99.5% NaCl






0.5% Citric Acid, 100 ppm SLS,
3180
1
0
3.54


99.5% NaCl






0.7% Citric Acid, 50 ppm SLS,
3710
0
0
3.14


99.3% NaCl






0.7% Citric Acid, 100 ppm SLS,
1020
0
0
3.13


99.3% NaCl






1.0% Citric Acid, 50 ppm SLS,
1840
0
0
2.82


99.0% NaCl






1.0% Citric Acid, 100 ppm SLS,
970
0
0
2.82


99.0% NaCl






2.0% Citric Acid, 50 ppm SLS,
114
0
0
2.41


98.0% NaCl






2.0% Citric Acid, 100 ppm SLS,
479
0
0
2.41


96.0% NaCl






4.0% Citric Acid, 50 ppm SLS,
6
0
0
2.12


96.0% NaCl






4.0% Citric Acid, 100 ppm SLS,
1
0
0
2.12


96.0% NaCl






6.0% Citric Acid, 50 ppm SLS,
1
0
0
1.99


94.0% NaCl









In another experiment, two sets of solutions were tested. The first set (samples 1-12 in Table 10 below) was prepared in hard tap water and contained about 17.0% by mass of the formulation. These samples were inoculated with 103 CFU/ml L. monocytogenes by the same procedure as described above. A second set of samples was prepared from brine taken from a ready-to-eat meat processing operation. The recirculated brine had been used to chill packaged meat for one week. After a week of use the brine typically contains various types of aerobic psychrotrophic and mesophilic bacteria. This experiment was done in order to determine if the additives would kill the microorganisms naturally occurring in actual process brine from a plant. Since the spent chill brine samples already contained NaCl citric acid and/or SLS was added to provide an effective concentration of additive. One set of these samples (samples 13-17) were inoculated with 103 L. monocytogenes and the other set (samples 18-22) contained only the naturally occurring organisms in the spent chill brine. Results are given in Table 10 below. The data indicate that at lower acid levels, the SLS increases the effectiveness of the mixture, but at higher acid levels, the SLS is not necessary. The results show the formulations are effective in hard water (27 gpg hardness). Other antimicrobials, such as quaternary ammonium compounds can lose significant activity in hard water, often necessitating further additives, such as EDTA as a chelating agent, to maintain antimicrobial activity. The results also demonstrate that the formulations effectively kill L. monocytogenes as well as the naturally occurring microorganisms in spent chill brine from an actual meat processing plant.









TABLE 10







Effects of Antimicrobial Salt Formulas in Hard Water


and in Spent Chill Brine













24



Time 0
2 hr
cfu/


Sample
cfu/ml
cfu/ml
ml













100% NaCl
760
1100
1100


0.3% Citric Acid, 100 ppm SLS, 99.7% NaCl
730
670
29


0.3% Citric Acid, 99.7% NaCl
1460
1330
830


0.5% Citric Acid, 100 ppm SLS, 99.5% NaCl
890
240
0


0.5% Citric Acid, 99.5% NaCl
1060
1170
330


0.7% Citric Acid, 100 ppm SLS, 99.3% NaCl
1010
14
0


0.7% Citric Acid, 99.3% NaCl
1040
1030
3


1.0% Citric Acid, 100 ppm SLS, 99.0% NaCl
840
0
0


1.0% Citric Acid, 99.0% NaCl
990
340
0


2.0% Citric Acid, 98.0% NaCl
910
0
0


4.0% Citric Acid, 96.0% NaCl
1110
0
0


6.0% Citric Acid, 94.0% NaCl
950
0
0


Brine Control with L. mono
1260
1290
600


1% Citric Acid in Brine with L. mono
1050
0
0


2% Citric Acid in Brine with L. mono
1140
0
0


1% Citric Acid + 50 ppm SLS in Brine
1090
0
0


with L. mono





2% Citric Acid + 50 ppm SLS in Brine
1070
0
0


with L. mono





Brine Control
6000
3100
2000


1% Citric Acid in Brine
2490
190
4


2% Citric Acid in Brine
1670
6
0


1% Citric Acid + 50 ppm SLS in Brine
2520
122
0


2% Citric Acid + 50 ppm SLS in Brine
1480
6
0









A test was run to determine if salts other than sodium chloride would show a synergistic antimicrobial effect with an acid and sodium lauryl sulfate. Solutions containing 0.6409 grams malic acid and 0.0107 grams sodium lauryl sulfate per liter were prepared with and without 107.0 grams of various salts (added on an anhydrous basis). Solutions were inoculated with E. coli described above and the amount of bacterial kill was measured to determine if the added salt caused an increase in the effectiveness of the acid/surfactant active ingredients. Results are shown in Table 11.









TABLE 11







Effect of Different Salts on the Antimicrobial


Action of Malic Acid/SLS










Solution (salt added)
% Kill of E. Coli






No salt addition
4.4% 



Sodium sulfate
87%



Magnesium chloride
56%



Potassium chloride
18%



Sodium chloride
78%



Potassium sulfate
34%



Calcium chloride
55%



Magnesium sulfate
93%









Tests run on solutions containing only the salt and no other ingredient indicate that sodium sulfate, potassium chloride and potassium sulfate provide no bacterial kill. Magnesium chloride solution provided 61% kill, calcium chloride provided 26% kill, and magnesium sulfate provided 10% kill. Thus, based on the data developed thus far, sodium sulfate, sodium chloride, and magnesium sulfate appear to significantly increase the effectiveness of the acid and/or surfactant antimicrobial agent, even though the salts provide little kill on their own.


The effectiveness of antimicrobial salt formulas was tested against L. monocytogenes in a biofilm. Stainless steel coupons (2×5 cm, type 302 stainless steel, 2B finish) were cleaned in acetone followed by an alkaline detergent and distilled water and then dried in an autoclave at 121° C. for 15 minutes. A culture of L. monocytogenes (Scott A—serotype 4b) was prepared by inoculating 10 mL of TSA and incubating overnight at 35° C. 50 mL of sterile TSA+0.6% yeast extract (YE) was aseptically dispensed into sterile disposable conical shaped plastic tubes and one drop of overnight grown L. mono culture was added to each tube. Inoculated tubes were incubated at 25° C. for approximately 48 hours. After the biofilm had formed on the coupons, a coupon was aseptically removed from the tube and gently rinsed with distilled water to remove unattached cells. Coupons were then immersed in cold antimicrobial test solution (−6.7° C.) and incubated over different time intervals (1 hour, 24 hours, and 5 days). After incubation period, the coupon was shaken in a tube containing 40 mL of sterile PBW and 10 sterile glass beads (4 mm) for 2 minutes two remove the cells attached to the coupon biofilm. The cells were plated in the PBW on TSA+0.6% YE using appropriate dilutions and incubated at 35° C. for 48 hours.


Results on triplicate samples of antimicrobial test solutions are given in Table below. Each solution contained 17% by weight of a formula consisting of the percentages of citric acid and SLS listed in Table 12 with the balance of the formula being NaCl in each case. The data indicate that not only are the antimicrobial salt solutions effective at killing bacteria suspended in solution, they are also effective at killing bacteria within a biofilm.









TABLE 12







Log Concentration of L. monocytogenes in


Antimicrobial Salt Solutions












24



Sample
1 Hour
Hours
5 days













0.3% citric acid, 100 ppm SLS
~5.08
4.59
1.38


0.3% citric acid, 100 ppm SLS
~4.90
3.85
1.79


0.3% citric acid, 100 ppm SLS
~4.81
3.48
1.92


0.3% citric acid, 500 ppm SLS
4.81
4.76
2.23


0.3% citric acid, 500 ppm SLS
4.90
3.48
2.18


0.3% citric acid, 500 ppm SLS
~5.18
3.48
2.36


0.7% citric acid, 100 ppm SLS
1.88
0
0


0.7% citric acid, 100 ppm SLS
2.02
0
0


0.7% citric acid, 100 ppm SLS
1.28
0
0


0.7% citric acid, 500 ppm SLS
0.70
1.00
0.90


0.7% citric acid, 500 ppm SLS
0.90
0.70
0.30


0.7% citric acid, 500 ppm SLS
0.85
0
0


2.0% citric acid, 100 ppm SLS
0
0
ND


2.0% citric acid, 100 ppm SLS
0
0
ND


2.0% citric acid, 100 ppm SLS
0
0
ND


2.0% citric acid, 500 ppm SLS
0
0
ND


2.0% citric acid, 500 ppm SLS
0
0
ND


2.0% citric acid, 500 ppm SLS
0
0
ND


6.0% citric acid, 100 ppm SLS
0
0
ND


6.0% citric acid, 100 ppm SLS
0
0
ND


6.0% citric acid, 100 ppm SLS
0
0
ND


6.0% citric acid, 500 ppm SLS
0
0
ND


6.0% citric acid, 500 ppm SLS
0
0
ND


6.0% citric acid, 500 ppm SLS
0
0
ND


12.0% citric acid, 100 ppm SLS
0
0
ND


12.0% citric acid, 100 ppm SLS
0
0
ND


12.0% citric acid, 100 ppm SLS
0
0
ND


12.0% citric acid, 500 ppm SLS
0
0
ND


12.0% citric acid, 500 ppm SLS
0
0
ND


12.0% citric acid, 500 ppm SLS
0
0
ND


Salt Control A
~5.04
~7.15
7.65


Salt Control B
~5.48
~7.15
7.42


Salt Control C
−5.48
−7.11
7.65


Water Control
−5.18
−7.18
7.54









Another set of experiments was done in order to determine the effectiveness of different acids and different types of surfactants in the antimicrobial salt formulations. In one experiment, test solutions containing ˜17% by weight of formulas containing various levels of sodium chloride, 100 ppm sodium lauryl sulfate, and various levels of different acids were tested for effectiveness in killing L. monocytogenes at cold temperatures. The same test procedure was used as described above (test solutions were plated on MOX TAL (Modified Oxford Medium with a Thin Agar Layer) with TSA). Results are given in Table 13. The controls were a solution of pure NaCl, a solution of a blend of 100 ppm SLS in NaCl, and a solution of a blend of 0.5% citric acid, 100 ppm SLS, and 99.5% NaCl. The subsequent test solutions were a 17% solution of a blend of NaCl and 100 ppm SLS with enough of the listed acid added to provide the same pH (˜3.6) as the 0.5% citric acid control.









TABLE 13







Effect of Different Acids on the Antimicrobial Action of


NaCl/Acid/SLS













Time 4




Time 0
Hours



Sample Solution Composition
(CFU/ml)
(CFU/ml)














Salt control
850
1380



Salt + SLS control
980
890



Salt + SLS + citric acid control
1230
18



Salt + SLS + succinic acid
1070
69



Salt + SLS + isoascorbic acid
1140
59



Salt + SLS + adipic acid
900
4



Salt + SLS + sorbic acid
820
500



Salt + SLS + acetic acid
1070
230



Salt + SLS + propionic acid
1440
6



Salt + SLS + lactic acid
1050
220



Salt + SLS + ascorbic acid
1230
54



Salt + SLS + formic acid
1930
38



Salt + SLS + phosphoric acid
1050
17



Salt + SLS + hydrochloric acid
1100
44



Salt + SLS + tartaric acid
1180
410



Salt + SLS + glutaric acid
610
180



Salt + SLS + benzoic acid
1020
17



Salt + SLS + salicylic acid
1100
5



Salt + SLS + sulfuric acid
830
0









In another experiment, test solutions containing 17% by weight of formulas containing 99.7% sodium chloride, 0.3% citric acid, and 500 ppm of various types of surfactants were tested for effectiveness in killing L. monocytogenes at cold temperatures. The same test procedure was used as described (test solutions were plated on MOX TAL (Modified Oxford Medium with a Thin Agar Layer) with TSA). Results are given in Table 14.









TABLE 14







Effect of Different Acids on the Antimicrobial Action of


NaCl/Acid/SLS Surfactant Tested










Time 0
Time 4 Hours


Surfactant Tested
(CFU/ml)
(CFU/ml)












Salt Control (no additive)
880
610


polyoxyethylene-polyoxypropylene block
820
610


polymer




sodium salt of sulfonated oleic acid
240
0


sodium xylene sulfonate
910
820


dodecyl diphenyl oxide disulfonate
0
0


sodium linear alkyl-benzene sulfonate
490
0


alpha-olefin sulfonate
370
0


alkylpolyglucoside
280
0


nonylphenol ethoxylate
460
0


fatty alkanolamide
470
0


alcohol ethoxylate
1080
1


lauramine oxide
2
0









One or more embodiments of the present invention can be operated under various sets of conditions. In one, a chilling brine maintained at a temperature of about −1.9° C. is employed. The chilling brine comprises, on a dry basis, between about 0.3% and about 1.0% citric acid. The citric acid concentration may be increased to as high as about 2.0%. Between about 100 and about 500 ppm SLS is utilized. The balance of the brine formulation is NaCl, and the formulation is mixed with water to a solution of about 9% to about 12%. In another chilling brine application, a chilling brine is maintained at a temperature of about −6.7° C. The chilling brine comprises between about 0.3% and about 1.0% citric acid. Again, the citric acid concentration may be increased to as high as about 2.0%. Between about 100 and about 500 ppm SLS is utilized. The balance of the brine formula is NaCl, and the formulation is mixed with water to a solution of about 15% to about 17%.


In accordance with another embodiment of the present invention, tests were conducted to determine the antimicrobial efficacy of a salt formulation containing a surfactant but no added acid. The effect of an aqueous solution comprising about 20 wt. % of various salt and salt/surfactant formulations on L. monocytogenes were tested in a manner directly analogous to that set forth above in connection with the data in Table 8. Table 15 sets forth the compositions and the L. monocytogenes population (stated as the log of the concentration of the bacteria) found after 4 hours of incubation. [Note that the compositions in Table 15, below, state the concentration in the solution, not in the salt concentrate. Since the solutions are 20 wt. % of the salt formulation, the concentration of surfactant in the salt formulation would be about five times the stated concentration in the solution.]









TABLE 15







Effect of Solutions of NaCl and SLS on L. monocytogenes











Population at 4 hours



Solution Composition
(log cfu/mL)













Water Control
4.61



20% NaCl (control)
4.32



50 ppm SLS (no NaCl)
3.90*



50 ppm SLS, 20% NaCl
0.85**





*The 3.90 value is an average of two runs that yielded values of 3.84 and 3.95.


**The 0.85 value is an average of two runs that yielded values of 0.70 and 1.00.






Further tests were run on a variety of different surfactants, demonstrating that a variety of different types of surfactants show a strong synergistic effect in combination with salt: sodium lauryl sulfate, linear alkylbenzene sulfonates, alcohol sulfates, alkyl sulfates, alkyl sulfonates, sodium alkyl methyltaurines, alpha-olefin sulfonates, alcohol ethoxylates, nonylphenyl ethoxylates, alkylpolyglucosides, fatty alcohols, fatty acids and fatty acid salts, lignosulfonates and lignin derivatives, hydroxypoly(oxyethylene) derivatives, fatty alkanolamides, fatty amine oxides, sodium dioctylsulfosuccinate, dodecylbenzene sulfonic acid and salts thereof, the sodium salt of sulfonated oleic acid, sodium dodecylbenzene sulfonate, lauramine oxide, dodecyldiphenyloxide-disulfonic acid and salts thereof.


Further examples of surfactants that may be used in some embodiments of the present invention include alkyl (C8-C24) benzenesulfonic acid and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; alkyl (C8-C18) sulfate and its ammonium, calcium, isopropylamine, magnesium, potassium, sodium, and zinc salts; diethylene glycol abietate, lauryl alcohol, lignosulfonate and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; nonyl, decyl, and undecyl glycoside mixture with a mixture of nonyl, decyl, and undecyl oligosaccharides and related reaction products (primarily decanol and undecanol) produced as an aqueous based liquid (50 to 65% solids) from the reaction of primary alcohols (containing 15 to 20% secondary alcohol isomers) in a ratio of 20% C9, 40% C10, and 40% C11 with carbohydrates (average glucose to alkyl chain ratio 1.3 to 1.8); α-(o,p-dinonylphenyl)-ω-hydroxypoly (oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters; the poly(oxyethylene) content averages 4-14 moles; α-(p-nonylphenyl)-ω-hydroxypoly(oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters, the poly(oxyethylene) content averages 4-14 moles or 30 moles; α-(p-nonylphenyl)-ω-hydroxypoly(oxyethylene) produced by the condensation of 1 mole nonylphenol with an average of 4-14 moles or 30-90 moles ethylene oxide; α-(p-nonylphenyl)-ω-hydroxypoly(oxyethylene) sulfate, ammonium, calcium, magnesium, potassium, sodium, and zinc salts; octyl and decyl glucosides mixture with a mixture of octyl and decyloligosaccharides and related reaction products (primarily n-decanol) produced as an aqueous based liquid (68-72% solids) from the reactions of straight chain alcohols (C8 (45%), C10 (55%)) with anhydrous glucose; oxidized pine lignin and its salts thereof; β-pinene polymers; polyethylene glycol (α-hydro-ω-hydroxypoly(oxyethylene)); mean molecular weight of 194 to 9500 amu; α-(p-tert-Butylphenyl)-ω-hydroxypoly(oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters; the poly(oxyethylene) content averages 4-12 moles; α-(o,p-dinonylphenyl)-w-hydroxypoly (oxyethylene) produced by the condensation of 1 mole of dinonylphenol with an average of 4-14 or 140-160 moles of ethylene oxide; sodium or potassium salts of fatty acids; sodium α-olefinsulfonate (sodium C14-C16) (Olefin sulfonate); sodium diisobutylnaphthalene sulfonate and/or sodium .isopropylisohexylnaphthalene sulfonate; sodium dodecylphenoxybenzenedisulfonate; sodium lauryl glyceryl ether sulfonate; sodium oleyl sulfate; sodium N-lauroyl-N-methyltaurine, sodium N-palmitoyl-N-methyltaurine and/or sodium N-oleoyl-N-methyltaurine; sodium monoalkyl and dialkyl (C8-C16) phenoxybenzenedisulfonate mixtures containing not less than 70% of the monoalkylated products; 2,4,7,9-tetramethyl-5-decyn-4,7-diol; and/or nonylphenol ethoxylates with average moles of ethoxylation between 4 and 30.


Further, in other embodiments the surfactant may be one or more of the following alcohol ethoxylates: α-Alkyl (C9-C18-ω-hydroxypoly(oxyethylene) with polyoxyethylene content of 2-30 moles; α-(p-alkylphenyl)-ω-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of alkylphenol (alkyl is a mixture of propylene tetramer and pentamer isomers and averages C13) with 6 moles ethylene oxide; α-Alkyl (C6-C14-ω-hydroxypoly(oxypropyylene) block copolymer with polyoxyethylene; polyoxypropylene content is 1-3 moles; polyoxyethylene content is 4-12 moles; average molecular weight is approximately 635 amu; α-Alkyl (C12-C15-ω-hydroxypoly(oxypropyylene)poly(oxyethylene) copolymers (where the poly(oxypropylene) content is 3-60 moles and the poly (oxyethylene) content is 5-80 moles; α-(p-Dodecylphenyl)-ω-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of dodecylphenol with an average of 4-14 or 30-70 moles ethylene oxide; ethylene oxide adducts of 2,4,7,9-tetramethyl-5-decynediol, the ethyelene oxide content averages 3.5, 10, or moles; α-Lauryl-ω-hydroxypoly(oxyethylene), sodium salt; the poly(oxyethylene) content is 34 moles; secondary alkyl (C11-C15) poly(oxyethylene) acetate salts; ethylene oxide content averages 5 moles; α-[p-1,1,3,3-tetramethylbutyl)phenyl-]-ω-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of p-1,1,3,3-tetramethylbutylphenol with a range of 1-14 or 30-70 moles ethylene oxide; tridecylpoly(oxyethylene) acetate salts where the ethylene oxide content average, 6-7 moles; poly(oxy-1,2-ethanediyl), α-(carboxymethyl)-ω-(nonylphenoxy) produced by the condensation o 1 mole nonylphenol with an average of 4-14 or 30-90 moles ethylene oxide with a molecular weight in the ranges 454-894 and 1598-4238; and/or α-Stearoyl-ω-hydroxy(polyoxyethylene), polyoxyethylene content averages either 8, 9, or 40 moles.


In yet other embodiments, the surfactant may be selected from the group having the formula: CH3(CH2)10—O(CH2CH2O)yH, where y=average moles of ethoxylation and is in the range of about 3-9.


Hence, in some embodiments of the invention the formulation may comprise an inorganic salt and surfactant such that when in solution the solution comprises surfactant in a concentration of: at least about 5 ppm, about 5-5000 ppm, about 5-500 ppm, about 10-25000 ppm, about 10-100 ppm, about 10-50 ppm, about 25-500 ppm, or about 500-1500 ppm.


Further, in other embodiments of the present invention, the ratio by weight of salt to surfactant may be greater than 29:1, greater than 1880:1, or greater than 1980:1.


In other embodiments of the current invention, solutions may comprise at least 2% of the dry composition, at least 5% of the dry composition, up to about 26% of the dry composition, between about 5% and 25% of the dry composition, between about 9% and 17% of the dry composition, or between about 12% and 15% of the dry composition.


Thus, the data indicate that embodiments of the present invention including solutions of salt and acid and/or surfactant provide efficient kill of bacteria even at temperatures below the freezing point of water. Salts such as sodium sulfate, sodium chloride, and magnesium sulfate act synergistically with the surfactant and/or acid to enhance the antimicrobial effectiveness. The formulations are shown to be effective in killing pathogenic bacteria such as L. monocytogenes. The formulas were shown to be effective both in freshly prepared brines and in actual spent process chill brine from a ready-to-eat meat plant. The levels of acid and/or surfactant may be varied to suit the particular application. In addition to effectively killing bacteria suspended in solutions, the some embodiments of the present invention are also shown to be effective at killing bacteria within a biofilm.


While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purpose of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein can be varied considerably without departing from the basic principles of the invention.

Claims
  • 1. An antimicrobial solution comprising on a dry basis: between about 100 ppm and about 1000 ppm surfactant selected from the group consisting of CH3(CH2)10-0(CH2CH2O)yH, where y=average moles of ethoxylation and is in the range 3-9; andbetween about 94% and about 99.9% by weight salt selected from the group consisting of sodium, potassium, magnesium, calcium, iron, ammonium salts of chloride, sulfate, nitrate, phosphate, carbonate, acetate, formate, propionate, hydroxypropionate, and hydroxide.
  • 2. The solution of claim 1 wherein the surfactant and salt in combination comprise at least about 2% by weight of the solution.
  • 3. The solution of claim 1 wherein the surfactant and salt in combination comprise at least about 5% by weight of the solution.
  • 4. A method for food processing comprising: contacting a food product to be processed with a chilling solution wherein the chilling solution comprises a combination of:a surfactant selected from the group consisting of CH3(CH2)10—O(CH2CH2O)yH, where y=average moles of ethoxylation and is in the range 3-9; anda salt selected from the group consisting of sodium, potassium, magnesium, calcium, iron, and ammonium salts of chloride, sulfate, nitrate, phosphate, carbonate, acetate, formate, propionate, hydroxypropionate, and hydroxide,wherein the salt and surfactant are on a dry basis between about 25 ppm and about 100,000 ppm by weight surfactant and between about 94% and about 99.9% by weight salt.
  • 5. The method of claim 4 wherein the ratio of the salt to the surfactant of the chilling solution is greater than about 29:1 by weight.
  • 6. The method of claim 4, wherein the chilling solution is maintained at a temperature of less than about 0° C.
  • 7. The method of claim 4, wherein the chilling solution is maintained at a temperature of less than about −6.7° C.
  • 8. The method of claim 4 wherein the surfactant and salt in combination comprise at least about 2% by weight of the chilling solution.
  • 9. The method of claim 4 wherein the surfactant and salt in combination comprise at least about 5% by weight of the chilling solution.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. application Ser. No. 11/335,167, filed 18 Jan. 2006, now U.S. Pat. No. 7,658,989, and entitled ANTIMICROBIAL SALT SOLUTIONS FOR FOOD SAFETY APPLICATIONS, which is a continuation-in-part of U.S. application Ser. No. 10/460,769, filed 12 Jun. 2003, now U.S. Pat. No. 7,090,882, naming the same inventors as the present application, and entitled ANTIMICROBIAL SALT SOLUTIONS FOR FOOD-SAFETY APPLICATIONS and U.S. application Ser. No. 11/303,260, filed 15 Dec. 2005, now U.S. Pat. No. 7,588, 696, and entitled ANTIMICROBIAL WATER SOFTENER AND SOLUTIONS, which claims the benefit of U.S. Provisional Application No. 60/636,337, filed 15 Dec. 2004, and entitled ANTIMICROBIAL WATER SOFTENER SALT AND SOLUTIONS and U.S. Provisional Application No. 60/637,674, filed 16 Dec. 2004, and entitled ANTIMICROBIAL WATER SOFTENER SALT AND SOLUTIONS. The entirety of each of these applications is incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2007/001320 1/18/2007 WO 00 7/9/2008
Publishing Document Publishing Date Country Kind
WO2007/084607 7/26/2007 WO A
US Referenced Citations (84)
Number Name Date Kind
2154449 Hoffman et al. Apr 1939 A
2854477 Steinhauer Sep 1958 A
3216932 Heiss et al. Nov 1965 A
3806615 Frankenfeld et al. Apr 1974 A
4002775 Kabara Jan 1977 A
4048342 Haas et al. Sep 1977 A
4067997 Kabara Jan 1978 A
4160820 Wagenknecht et al. Jul 1979 A
4189481 Kabara Feb 1980 A
4298624 Mehring et al. Nov 1981 A
4299852 Ueno et al. Nov 1981 A
4363763 Peterson Dec 1982 A
4469635 Peterson Sep 1984 A
4485029 Kato et al. Nov 1984 A
4539212 Hunter Sep 1985 A
4576728 Stoddart Mar 1986 A
4722941 Eckert et al. Feb 1988 A
4749508 Cockrell, Jr. et al. Jun 1988 A
4749561 Lane et al. Jun 1988 A
4820449 Menke et al. Apr 1989 A
4839086 Zaid Jun 1989 A
4908147 Tsao et al. Mar 1990 A
4921694 Hoppe et al. May 1990 A
4938953 Pena et al. Jul 1990 A
5069922 Brotsky et al. Dec 1991 A
5079036 Roe et al. Jan 1992 A
5093140 Watanabe Mar 1992 A
5143739 Bender et al. Sep 1992 A
5166177 Thomas et al. Nov 1992 A
5208257 Kabara May 1993 A
5219887 Andrews et al. Jun 1993 A
5283073 Bender et al. Feb 1994 A
5284833 McAnalley et al. Feb 1994 A
5364650 Guthery Nov 1994 A
5378731 Andrews et al. Jan 1995 A
5380756 Andrews et al. Jan 1995 A
5460802 Asami et al. Oct 1995 A
5460833 Andrews et al. Oct 1995 A
5490992 Andrews et al. Feb 1996 A
5520575 Dickson May 1996 A
5569461 Andrews Oct 1996 A
5585028 Berger Dec 1996 A
5622708 Richter et al. Apr 1997 A
5632153 Ricklefs et al. May 1997 A
5756107 Hahn et al. May 1998 A
5792473 Gergely et al. Aug 1998 A
5851974 Sandhu Dec 1998 A
5909745 Ali et al. Jun 1999 A
5968539 Beerse et al. Oct 1999 A
5980375 Anderson et al. Nov 1999 A
6121215 Rau Sep 2000 A
6183757 Beerse et al. Feb 2001 B1
6190675 Beerse et al. Feb 2001 B1
6194370 Williams, Jr. et al. Feb 2001 B1
6197315 Beerse et al. Mar 2001 B1
6197738 Regutti Mar 2001 B1
6214363 Beerse et al. Apr 2001 B1
6214783 Gambogi et al. Apr 2001 B1
6217887 Beerse et al. Apr 2001 B1
6231843 Hoelzel et al. May 2001 B1
6284259 Beerse et al. Sep 2001 B1
6287577 Beerse et al. Sep 2001 B1
6331261 Waatti et al. Dec 2001 B1
6376438 Rosenberger et al. Apr 2002 B1
6407143 Even et al. Jun 2002 B1
6432885 Vollmer Aug 2002 B1
6436445 Hei et al. Aug 2002 B1
6475499 Maubru et al. Nov 2002 B2
6867233 Roselle et al. Mar 2005 B2
7090882 Koefod et al. Aug 2006 B2
7588696 Koefod Sep 2009 B2
7658959 Koefod et al. Feb 2010 B2
7883732 Koefod et al. Feb 2011 B2
20020004464 Nelson et al. Jan 2002 A1
20020098210 Hahn et al. Jul 2002 A1
20020182267 Kleinberg et al. Dec 2002 A1
20030176500 Molly et al. Sep 2003 A1
20030180377 Ramirez et al. Sep 2003 A1
20030185902 Hei et al. Oct 2003 A1
20040253352 Koefod et al. Dec 2004 A1
20050096245 Hei et al. May 2005 A1
20060110506 Burwell et al. May 2006 A1
20060157415 Koefod et al. Jul 2006 A1
20070087093 Koefod Apr 2007 A1
Foreign Referenced Citations (44)
Number Date Country
2589507 Jun 2006 CA
243 145 Oct 1987 EP
244 144 Nov 1987 EP
312 519 Apr 1989 EP
368 622 May 1990 EP
0423923 Jul 1990 EP
530 861 Mar 1993 EP
633 767 Jan 1995 EP
670 160 Sep 1995 EP
713 096 May 1996 EP
874 988 Nov 1998 EP
891 711 Jan 1999 EP
8800463 Jan 1988 WO
9221320 Dec 1992 WO
9300100 Jan 1993 WO
9319154 Sep 1993 WO
9319159 Sep 1993 WO
9409106 Apr 1994 WO
9507616 Mar 1995 WO
9532705 Dec 1995 WO
9619181 Jun 1996 WO
9722878 Jun 1997 WO
9809520 Mar 1998 WO
9855093 Dec 1998 WO
9855095 Dec 1998 WO
9920729 Apr 1999 WO
9936494 Jul 1999 WO
9966020 Dec 1999 WO
0001238 Jan 2000 WO
0022082 Apr 2000 WO
0030460 Jun 2000 WO
0061105 Oct 2000 WO
0071183 Nov 2000 WO
0116267 Mar 2001 WO
0141927 Jun 2001 WO
0143549 Jun 2001 WO
0155287 Aug 2001 WO
0215809 Feb 2002 WO
0224845 Mar 2002 WO
0250223 Jun 2002 WO
2005000029 Jan 2005 WO
2006066253 Jun 2006 WO
2007084607 Jul 2007 WO
2007139722 Dec 2007 WO
Non-Patent Literature Citations (10)
Entry
R.E Wolley, DVM, PhD.: EDTA-tris Potentiation of Antimicrobial Agents, Modern Veterinary Ptactice, pp. 113-116, Feb. 1983.
Rachel Schemmel, et al.: Monolaurin as an Anticaries Agent, Symposium on the Pharmacological Effect of Lipids, St. Louis, The American Oil Chemist's Society, Champaign, Illinois, p. 37 (Date not available).
Nobuyuki Katp et al.: Combined Effect of Citric and Polyphosphoric Acid on the Antibacterial Activity of Monoglycerides, pp. 2-9, Apr. 10, 1976.
Nobuyuki Kato, et al.: Combined Effect of Different Drugs on the Antibacterial Activity of Fatty Acids and Their Esters, pp. 1-7, Sep. 25, 1975.
International Search Report for PCT/US05/46150, dated Sep. 5, 2006, 1 pg.
International Search Report fro PCT/US07/01320, dated Dec. 5, 2007, 2 pgs.
International Search Report for PCT/US07/11910, dated Oct. 24, 2007, 1 pg.
International Search Report for PCT/US04/18862, dated Jun. 20, 2005, 1 pg.
The site “diphenyl oxide” at http://www.thegoodscentscompany.com/data/rw1004531.htmp, downloaded Nov. 23, 2008.
Canadian Intellectual Property Office, Office Action for CA 2589517, Jul. 13, 2011 citing the European reference cited above (EP0423923).
Related Publications (1)
Number Date Country
20090011097 A1 Jan 2009 US
Continuation in Parts (1)
Number Date Country
Parent 11335167 Jan 2006 US
Child 12087560 US